Literature DB >> 1589243

Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat.

Gong Qian-Ling1, Jan Hedner, Roland Björkman, Thomas Hedner.   

Abstract

The effects of the major morphine metabolites, morphine-3-glucuronide and morphine-6-glucuronide, on nociception were assessed by the tail-flick, hot-plate and writhing tests in the rat. Morphine-3-glucuronide (M3G) 1.1 x 10(-9) mol (0.5 micrograms) or saline was injected intracerebroventricularly (i.c.v.) or intrathecally (i.t.) followed by a second injection of 2.0 x 10(-10) mol (0.1 microgram) or 2.0 x 10(-11) mol (0.01 microgram) morphine-6-glucuronide (M6G) 10 min later. Administration of M3G (i.c.v.) significantly attenuated the antinociceptive effects of M6G in the hot-plate test. After i.t. administration, the antinociceptive effect of M6G in all three tests was significantly reduced in the M3G pretreated group compared to the group receiving saline. The ventilatory effects of 4.0 x 10(-9)-1.0 x 10(-8) mol (2-5 micrograms) M6G and 1.7-2.2 x 10(-8) mol (8-10 micrograms) M3G given i.c.v. were studied by a whole-body plethysmographic technique in halothane anaesthetized rats. Separate groups of rats received M3G followed by M6G injection or vice versa. In animals receiving M3G there was a prevention or attenuation of the M6G induced depression of respiratory frequency, tidal volume and minute ventilation compared to control groups receiving M6G in combination with saline. These results show that M3G may functionally antagonize the central antinociceptive effects as well as the ventilatory depression induced by M6G. Interestingly, M3G was more potent in antagonizing the M6G-induced analgesia after i.t. administration than that after i.c.v. administration, which may suggest that the spinal cord is more sensitive to the non-opioid excitatory effects of M3G than supraspinal structures.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1589243     DOI: 10.1016/0304-3959(92)90065-J

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  28 in total

1.  Intranasal delivery--modification of drug metabolism and brain disposition.

Authors:  Yin Cheong Wong; Zhong Zuo
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

2.  Analgesic and immunomodulatory effects of codeine and codeine 6-glucuronide.

Authors:  V Srinivasan; D Wielbo; J Simpkins; J Karlix; K Sloan; I Tebbett
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

3.  Pharmacokinetics of oral morphine sulfate in dogs: a comparison of sustained release and conventional formulations.

Authors:  S E Dohoo; R A Tasker
Journal:  Can J Vet Res       Date:  1997-10       Impact factor: 1.310

Review 4.  Strategies for the treatment of cancer pain in the new millennium.

Authors:  C Ripamonti; E D Dickerson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

6.  A successful case in cancer pain management with high-dose intravenous morphine.

Authors:  T Ishikawa; K Hiraga
Journal:  J Anesth       Date:  1995-12       Impact factor: 2.078

Review 7.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

8.  Effects of morphine metabolites on micturition in normal, unanaesthetized rats.

Authors:  Y Igawa; D Westerling; A Mattiasson; K E Andersson
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

9.  Morphine induces hyperalgesia without involvement of μ-opioid receptor or morphine-3-glucuronide.

Authors:  Maarten Swartjes; René A G Mooren; Amanda R Waxman; Caroline Arout; Koen van de Wetering; Jan den Hartigh; Jos H Beijnen; Benjamin Kest; Albert Dahan
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

10.  Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids.

Authors:  Glynn A Morrish; David J R Foster; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.